Blocking female sex hormone may help fight immune disease

London: Researchers have found that a female sex hormone may help patients suffering from a serious immune disease which is majorly represented by the thickening of the skin. The findings showed that blocking oestrogens -- the female hormones -- might help women suffering from systemic sclerosis (SSc). SSc -- also known as scleroderma, which means 'hard skin' -- is an autoimmune disease affecting multiple organs and which predominantly affects women.  The excessive production of proteins such as collagen by fibroblasts in the body results in the thickening and hardening of the skin, particularly of the hands and face -- a defining feature of SSc.  Also, the condition increased in women after the menopause as oestrogens -- that were found to significantly slow down fibrosis (the thickening of the skin) -- decreased in menopause. "Inhibiting this oestrogen showed a consistent and significant deterioration of the process of skin fibrosis," said Jerome Avouac from Paris Descartes University in France. In some SSc patients, disease progression is very rapid, with skin thickening extending beyond the extremities.  The widespread fibrosis (thickening) involving the internal organs can prove a survival risk in such patients and can also be considered as a valuable marker of the overall disease severity. For the study, the effect of oestrogen inhibition was evaluated in mouse models of skin fibrosis using two techniques.  Firstly, in a population of mice in whom gene inactivation had knocked out the key receptor that responds to oestrogens and secondly using tamoxifen, which is a hormone therapy, that blocks the action of oestrogen.  "Having confirmed those oestrogens indeed play a role in protecting against skin fibrosis in experimental models representative of SSc, the next step will be to begin investigating the potential role of hormone therapies as a treatment of SSc skin disease," Avouac noted. The findings were presented at the European League Against Rheumatism Annual Congress (EULAR 2016) in London, recently. Currently, no therapy with an acceptable toxicity profile has proven to be effective in the treatment of SSc skin disease.